Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Profile

Kian Behbakht

Concepts (455)

Concepts are derived automatically from a person's publications.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Ovarian Neoplasms
47
2025
564
5.630
 Why?
Poly(ADP-ribose) Polymerase Inhibitors
10
2025
115
1.630
 Why?
Endometrial Neoplasms
11
2025
199
1.190
 Why?
Drug Resistance, Neoplasm
17
2024
800
1.100
 Why?
Peritoneal Neoplasms
7
2024
93
1.090
 Why?
Antineoplastic Combined Chemotherapy Protocols
9
2020
1689
0.910
 Why?
Genital Neoplasms, Female
6
2020
89
0.890
 Why?
Uterine Cervical Neoplasms
8
2017
257
0.890
 Why?
Cystadenocarcinoma, Serous
6
2024
77
0.820
 Why?
Biomarkers, Tumor
9
2025
1263
0.740
 Why?
Hysterectomy
4
2018
129
0.730
 Why?
Antineoplastic Agents
10
2023
2127
0.720
 Why?
Neoplasm Recurrence, Local
8
2025
1061
0.720
 Why?
Fallopian Tube Neoplasms
6
2024
17
0.700
 Why?
TNF-Related Apoptosis-Inducing Ligand
5
2017
52
0.650
 Why?
Gelatin
2
2016
52
0.590
 Why?
Neoplasms, Glandular and Epithelial
3
2015
49
0.570
 Why?
Thrombin
2
2016
152
0.570
 Why?
Models, Economic
1
2018
58
0.570
 Why?
Claudin-4
4
2025
15
0.560
 Why?
Hyperthermia, Induced
1
2018
116
0.540
 Why?
Histone-Lysine N-Methyltransferase
3
2024
135
0.530
 Why?
Female
88
2025
73366
0.530
 Why?
Cell Line, Tumor
21
2025
3407
0.520
 Why?
Pelvic Infection
1
2016
4
0.510
 Why?
Homeodomain Proteins
3
2012
506
0.500
 Why?
Tissue Adhesives
1
2016
19
0.500
 Why?
Cost-Benefit Analysis
1
2018
592
0.470
 Why?
Neoplastic Cells, Circulating
2
2017
79
0.470
 Why?
Women
1
2015
50
0.450
 Why?
Sirolimus
2
2016
276
0.420
 Why?
Vagina
6
2016
187
0.410
 Why?
Middle Aged
50
2025
33465
0.390
 Why?
Humans
92
2025
137624
0.380
 Why?
Health Knowledge, Attitudes, Practice
2
2015
1331
0.380
 Why?
Antibodies, Neoplasm
1
2012
34
0.370
 Why?
Neoplasm Staging
15
2024
1368
0.360
 Why?
Cisplatin
2
2015
320
0.350
 Why?
Aged
38
2025
23924
0.350
 Why?
Aged, 80 and over
19
2025
7593
0.340
 Why?
Neoadjuvant Therapy
4
2020
400
0.320
 Why?
Pelvic Exenteration
1
2009
11
0.320
 Why?
Robotic Surgical Procedures
3
2016
130
0.310
 Why?
Apoptosis
8
2019
2554
0.310
 Why?
Leiomyosarcoma
3
2020
28
0.310
 Why?
Uterine Neoplasms
4
2019
109
0.310
 Why?
Phthalazines
2
2019
45
0.310
 Why?
Paclitaxel
3
2019
230
0.310
 Why?
Cytoreduction Surgical Procedures
2
2020
63
0.310
 Why?
Receptors, TNF-Related Apoptosis-Inducing Ligand
3
2017
30
0.310
 Why?
Pyrimidines
3
2019
471
0.300
 Why?
Health Personnel
1
2015
711
0.290
 Why?
Tumor Microenvironment
2
2024
676
0.290
 Why?
Carcinoma, Endometrioid
3
2019
50
0.290
 Why?
Chemotherapy, Adjuvant
2
2020
383
0.290
 Why?
Carbazoles
1
2008
83
0.280
 Why?
Gene Expression Regulation, Neoplastic
8
2025
1392
0.280
 Why?
Caffeine
1
2008
68
0.280
 Why?
Azepines
2
2019
90
0.280
 Why?
Papanicolaou Test
2
2004
43
0.270
 Why?
Adult
32
2025
37947
0.270
 Why?
Vaginal Smears
2
2004
57
0.270
 Why?
Clinical Competence
1
2015
1128
0.270
 Why?
Piperazines
2
2019
350
0.260
 Why?
Protein Kinase C
1
2008
260
0.260
 Why?
Postoperative Complications
6
2020
2655
0.250
 Why?
Hemostasis, Surgical
2
2016
22
0.240
 Why?
Laparotomy
2
2015
109
0.230
 Why?
Urban Health
1
2004
92
0.220
 Why?
Adenocarcinoma
4
2015
935
0.220
 Why?
Disease-Free Survival
7
2017
672
0.220
 Why?
Genomic Instability
1
2025
53
0.220
 Why?
Indoles
2
2025
413
0.220
 Why?
Fallopian Tubes
1
2024
31
0.210
 Why?
Histocompatibility Antigens
2
2024
105
0.210
 Why?
Genetic Therapy
2
2014
297
0.200
 Why?
Pyrazoles
2
2020
424
0.200
 Why?
Prognosis
9
2024
4009
0.200
 Why?
Lipids
2
2025
671
0.200
 Why?
Uterine Cervical Dysplasia
2
2003
42
0.190
 Why?
Adenocarcinoma, Clear Cell
2
2021
14
0.190
 Why?
Neoplasm Grading
5
2024
307
0.190
 Why?
Radiosurgery
1
2025
344
0.190
 Why?
Leiomyoma
2
2019
77
0.180
 Why?
Hospitals, Public
1
2001
28
0.180
 Why?
Healthcare Disparities
2
2018
654
0.170
 Why?
Piperidines
2
2019
207
0.170
 Why?
BRCA2 Protein
3
2019
63
0.170
 Why?
Hospitals, University
1
2001
182
0.170
 Why?
Cervix Uteri
3
2011
48
0.170
 Why?
Vulvar Neoplasms
1
2020
13
0.170
 Why?
Early Detection of Cancer
1
2025
447
0.170
 Why?
Treatment Outcome
11
2020
10823
0.160
 Why?
Epoxy Compounds
1
2020
33
0.160
 Why?
Machine Learning
1
2025
506
0.160
 Why?
Mutation
5
2019
3956
0.160
 Why?
Carnitine O-Palmitoyltransferase
1
2020
46
0.160
 Why?
Rad51 Recombinase
1
2019
15
0.160
 Why?
Cell Movement
2
2016
967
0.160
 Why?
Up-Regulation
2
2020
840
0.160
 Why?
Enoxaparin
1
2020
63
0.160
 Why?
Vaccines, Conjugate
1
2019
65
0.160
 Why?
Receptors, Adiponectin
1
2019
19
0.160
 Why?
Neoplasms
4
2017
2661
0.150
 Why?
Poly(ADP-ribose) Polymerases
1
2019
98
0.150
 Why?
Interleukin-12
2
2014
121
0.150
 Why?
Pyridones
1
2020
168
0.150
 Why?
Sequence Analysis, RNA
2
2019
452
0.150
 Why?
CD8-Positive T-Lymphocytes
1
2024
904
0.140
 Why?
Lymph Node Excision
2
2020
170
0.140
 Why?
Adjuvants, Immunologic
1
2019
226
0.140
 Why?
Patient Acceptance of Health Care
1
2004
807
0.140
 Why?
Cancer Vaccines
1
2019
172
0.140
 Why?
Cost Savings
1
2018
84
0.140
 Why?
Ovariectomy
2
2015
152
0.140
 Why?
Oncologists
1
2018
38
0.140
 Why?
Sarcoma
1
2020
184
0.140
 Why?
Cell Growth Processes
2
2008
52
0.140
 Why?
Animals
14
2024
36935
0.140
 Why?
Dose-Response Relationship, Drug
4
2008
2057
0.140
 Why?
Aurora Kinase A
1
2017
56
0.140
 Why?
Antineoplastic Agents, Phytogenic
1
2019
191
0.140
 Why?
Breast Neoplasms
4
2019
2249
0.140
 Why?
Pregnancy Complications, Infectious
1
2002
394
0.140
 Why?
Leukocyte Common Antigens
1
2017
89
0.130
 Why?
Anion Transport Proteins
1
2017
9
0.130
 Why?
Survival Rate
5
2020
1956
0.130
 Why?
Salpingectomy
2
2015
13
0.130
 Why?
Fatty Acids
1
2020
443
0.130
 Why?
Gestational Trophoblastic Disease
1
2016
6
0.130
 Why?
beta Catenin
1
2019
253
0.130
 Why?
Sexual Dysfunctions, Psychological
1
2017
34
0.130
 Why?
Curettage
1
2016
8
0.130
 Why?
Keratins
1
2017
173
0.130
 Why?
Mice
10
2024
17789
0.130
 Why?
Megestrol Acetate
1
2016
2
0.130
 Why?
Sexual Dysfunction, Physiological
1
2017
64
0.130
 Why?
Minority Groups
1
2018
266
0.130
 Why?
Carcinoma, Neuroendocrine
1
2016
41
0.120
 Why?
Neoplasms, Squamous Cell
1
1996
4
0.120
 Why?
Standard of Care
1
2016
72
0.120
 Why?
Colony Count, Microbial
1
2016
120
0.120
 Why?
Gynecology
1
2018
168
0.120
 Why?
Risk Factors
6
2016
10401
0.120
 Why?
Venous Thromboembolism
1
2020
316
0.120
 Why?
Medroxyprogesterone Acetate
1
2015
36
0.120
 Why?
Adenoviridae
1
1996
193
0.120
 Why?
Brachytherapy
1
2016
121
0.120
 Why?
Cell Survival
4
2025
1120
0.120
 Why?
Keratin-5
1
2015
50
0.120
 Why?
Gene Expression Profiling
2
2019
1768
0.120
 Why?
Molecular Targeted Therapy
1
2018
410
0.120
 Why?
Anticoagulants
1
2020
664
0.120
 Why?
Tretinoin
1
1996
123
0.120
 Why?
Reverse Transcriptase Polymerase Chain Reaction
1
2017
972
0.120
 Why?
Tamoxifen
1
2016
202
0.120
 Why?
Chemoradiotherapy
1
2016
221
0.110
 Why?
Combined Modality Therapy
4
2020
1228
0.110
 Why?
Immunohistochemistry
3
2016
1730
0.110
 Why?
Cell Proliferation
5
2024
2476
0.110
 Why?
Antineoplastic Agents, Hormonal
1
2015
161
0.110
 Why?
CA-125 Antigen
2
2008
14
0.110
 Why?
Abdominal Abscess
1
2014
27
0.110
 Why?
Xenograft Model Antitumor Assays
3
2024
872
0.110
 Why?
Surgeons
1
2018
291
0.110
 Why?
Mice, SCID
2
2012
366
0.110
 Why?
Kaplan-Meier Estimate
4
2020
885
0.110
 Why?
Glycoproteins
1
2015
342
0.110
 Why?
Endometrium
1
2014
58
0.110
 Why?
Reoperation
1
2016
574
0.110
 Why?
Lipid Metabolism
1
2017
518
0.100
 Why?
Cytokines
1
2002
2085
0.100
 Why?
Immunotherapy
1
2018
640
0.100
 Why?
Cell Cycle
2
2025
601
0.100
 Why?
Interpersonal Relations
1
2017
398
0.100
 Why?
Double-Blind Method
4
2025
1997
0.100
 Why?
Case-Control Studies
5
2025
3567
0.100
 Why?
Quality of Health Care
1
2018
642
0.100
 Why?
Proto-Oncogene Proteins c-akt
2
2016
437
0.100
 Why?
Transforming Growth Factor beta
1
1996
483
0.100
 Why?
Pelvic Neoplasms
1
2013
26
0.100
 Why?
Models, Biological
3
2019
1782
0.100
 Why?
Genes, Tumor Suppressor
3
1998
86
0.100
 Why?
Plasmids
1
2014
363
0.100
 Why?
Young Adult
5
2020
13226
0.100
 Why?
Antigens, CD
1
2015
523
0.100
 Why?
Gardnerella vaginalis
2
2002
4
0.090
 Why?
Escherichia coli
1
2016
815
0.090
 Why?
Antibody Specificity
1
2012
189
0.090
 Why?
RNA, Messenger
2
2012
2834
0.090
 Why?
Cell Division
2
2008
794
0.090
 Why?
Endocrine Gland Neoplasms
1
2011
1
0.090
 Why?
Transplantation, Heterologous
1
2012
194
0.090
 Why?
Neoplastic Stem Cells
1
2015
400
0.090
 Why?
RNA, Small Interfering
3
2020
622
0.090
 Why?
Cyclin D1
1
2011
68
0.090
 Why?
Drug Synergism
2
2011
381
0.090
 Why?
Proteasome Inhibitors
1
2011
46
0.090
 Why?
MicroRNAs
1
2017
690
0.090
 Why?
Adenocarcinoma, Mucinous
1
2011
80
0.080
 Why?
DNA
1
2017
1460
0.080
 Why?
Transfection
2
2007
945
0.080
 Why?
Cadherins
1
2011
206
0.080
 Why?
Peptides
1
2015
985
0.080
 Why?
Neoplasm Invasiveness
3
2016
509
0.080
 Why?
Lymphoma
1
2011
212
0.080
 Why?
Inflammation
1
2020
2838
0.080
 Why?
Age Factors
5
2016
3299
0.080
 Why?
Skin Transplantation
1
2009
84
0.080
 Why?
Anastomosis, Surgical
1
2009
153
0.070
 Why?
Urokinase-Type Plasminogen Activator
1
2008
29
0.070
 Why?
Papillomaviridae
2
2002
120
0.070
 Why?
G2 Phase
1
2008
38
0.070
 Why?
Adaptor Proteins, Signal Transducing
1
2011
429
0.070
 Why?
Adolescent
5
2020
21561
0.070
 Why?
TOR Serine-Threonine Kinases
1
2011
411
0.070
 Why?
Radiation-Protective Agents
1
2008
26
0.070
 Why?
Rectum
1
2009
185
0.070
 Why?
Heterografts
2
2019
135
0.070
 Why?
Genes, BRCA1
2
1998
40
0.070
 Why?
Models, Statistical
1
2011
665
0.070
 Why?
Microsatellite Instability
2
2019
42
0.070
 Why?
Class I Phosphatidylinositol 3-Kinases
2
2019
95
0.070
 Why?
Urinary Bladder
1
2009
183
0.070
 Why?
Cell Culture Techniques
2
2020
362
0.070
 Why?
Cysteine
1
2008
204
0.060
 Why?
Tumor Suppressor Protein p53
3
2019
528
0.060
 Why?
Gynecologic Surgical Procedures
2
2020
63
0.060
 Why?
PTEN Phosphohydrolase
2
2019
167
0.060
 Why?
Models, Animal
1
2008
383
0.060
 Why?
Adenosarcoma
2
2005
2
0.060
 Why?
Proportional Hazards Models
3
2020
1260
0.060
 Why?
Follow-Up Studies
4
2020
5122
0.060
 Why?
Retrospective Studies
6
2020
15620
0.060
 Why?
Signal Transduction
4
2012
5084
0.060
 Why?
Indazoles
2
2019
69
0.060
 Why?
Maintenance Chemotherapy
1
2025
35
0.060
 Why?
Polymerase Chain Reaction
4
2002
1061
0.060
 Why?
Length of Stay
3
2015
1209
0.060
 Why?
Colposcopy
2
2003
18
0.060
 Why?
Intestinal Neoplasms
1
2005
29
0.060
 Why?
Cell Count
2
2015
324
0.060
 Why?
Ovary
1
2007
221
0.060
 Why?
Neoplasm Proteins
3
1998
432
0.060
 Why?
Ultraviolet Rays
1
2008
396
0.060
 Why?
Sexual Behavior
1
2009
485
0.060
 Why?
Germ-Line Mutation
2
1996
172
0.060
 Why?
Chicago
1
2004
61
0.060
 Why?
United States
5
2022
14869
0.060
 Why?
Disease Progression
3
2019
2753
0.060
 Why?
Tumor Cells, Cultured
2
1996
957
0.060
 Why?
Peptide Fragments
1
2008
706
0.050
 Why?
Antioxidants
1
2008
585
0.050
 Why?
Blood Loss, Surgical
2
2015
100
0.050
 Why?
Transcription Factors
4
2011
1720
0.050
 Why?
Survival Analysis
4
2020
1315
0.050
 Why?
Activating Transcription Factor 6
1
2023
20
0.050
 Why?
Receptors, Estrogen
2
2015
436
0.050
 Why?
Transcription Factor AP-1
1
2023
91
0.050
 Why?
X-ray Repair Cross Complementing Protein 1
1
2022
13
0.050
 Why?
Neoplasm Metastasis
2
2015
655
0.050
 Why?
Medical Oncology
1
2024
292
0.050
 Why?
Vaginal Neoplasms
1
2001
18
0.050
 Why?
Trichomonas vaginalis
1
2002
14
0.050
 Why?
Gene Expression
1
2007
1503
0.050
 Why?
Phosphatidylinositol 3-Kinases
2
2016
366
0.050
 Why?
Yeasts
1
2002
53
0.050
 Why?
Women's Health
1
2004
372
0.050
 Why?
Vaginosis, Bacterial
1
2001
12
0.050
 Why?
Risk Assessment
3
2016
3458
0.050
 Why?
Vaginal Diseases
1
2001
21
0.050
 Why?
Cell Nucleus
1
2025
620
0.040
 Why?
Endometriosis
1
2001
51
0.040
 Why?
Quality of Life
2
2025
2891
0.040
 Why?
Pregnancy
3
2016
6771
0.040
 Why?
DNA, Neoplasm
2
1998
161
0.040
 Why?
DNA Primers
1
2002
514
0.040
 Why?
Vulvectomy
1
2020
2
0.040
 Why?
Epithelial Cells
1
2007
1097
0.040
 Why?
Dermatofibrosarcoma
1
2020
9
0.040
 Why?
Histiocytoma, Malignant Fibrous
1
2020
6
0.040
 Why?
Hospitals, Urban
1
2001
134
0.040
 Why?
Clinical Trials, Phase I as Topic
1
2020
50
0.040
 Why?
Databases, Factual
2
2016
1357
0.040
 Why?
Disease Models, Animal
2
2024
4287
0.040
 Why?
Medically Uninsured
1
2001
130
0.040
 Why?
Liposarcoma
1
2020
27
0.040
 Why?
Alleles
3
2017
892
0.040
 Why?
DNA Repair
1
2022
231
0.040
 Why?
Anoikis
1
2020
31
0.040
 Why?
Hemocyanins
1
2019
62
0.040
 Why?
Interleukin-10
1
2002
302
0.040
 Why?
Prospective Studies
4
2016
7599
0.040
 Why?
Chitinase-3-Like Protein 1
1
2019
19
0.040
 Why?
Diagnosis, Differential
2
2019
1483
0.040
 Why?
Rhabdomyosarcoma
1
2020
72
0.040
 Why?
Logistic Models
1
2004
2071
0.040
 Why?
Radiotherapy
1
2020
201
0.040
 Why?
Enzyme-Linked Immunosorbent Assay
1
2002
853
0.040
 Why?
Neoplasms, Cystic, Mucinous, and Serous
1
2019
27
0.040
 Why?
SEER Program
1
2020
226
0.040
 Why?
Intramolecular Oxidoreductases
1
2019
68
0.040
 Why?
DNA Damage
1
2022
421
0.040
 Why?
DNA Polymerase II
1
2019
37
0.040
 Why?
Poly-ADP-Ribose Binding Proteins
1
2019
35
0.040
 Why?
Lymphatic Metastasis
1
2020
339
0.040
 Why?
Chromosomes, Human, Pair 7
1
1998
18
0.040
 Why?
Gene Knockdown Techniques
1
2020
328
0.040
 Why?
Cell Cycle Checkpoints
1
2019
98
0.040
 Why?
Cytoskeletal Proteins
1
2019
158
0.040
 Why?
Mechanistic Target of Rapamycin Complex 1
1
2019
125
0.040
 Why?
Mitosis
1
2019
192
0.040
 Why?
Microtubule-Associated Proteins
1
2019
196
0.040
 Why?
Europe
1
2019
414
0.030
 Why?
Interleukin-1
1
2002
965
0.030
 Why?
Colorectal Neoplasms, Hereditary Nonpolyposis
1
1998
35
0.030
 Why?
AMP-Activated Protein Kinases
1
2019
197
0.030
 Why?
Image Cytometry
1
2017
9
0.030
 Why?
Interleukin-6
1
2002
778
0.030
 Why?
Wnt Signaling Pathway
1
2019
192
0.030
 Why?
Chromosomes, Human, Pair 14
1
1997
21
0.030
 Why?
Ganciclovir
1
1996
53
0.030
 Why?
Chromosome Deletion
1
1997
115
0.030
 Why?
Hospitals, Private
1
2016
12
0.030
 Why?
Health Facility Size
1
2016
11
0.030
 Why?
Socioeconomic Factors
1
2001
1285
0.030
 Why?
Chorionic Gonadotropin
1
2016
80
0.030
 Why?
Mass Spectrometry
1
2019
741
0.030
 Why?
Oxidation-Reduction
1
2020
1062
0.030
 Why?
Time Factors
2
2019
6831
0.030
 Why?
Ifosfamide
1
1996
37
0.030
 Why?
Cell Separation
1
2017
319
0.030
 Why?
AC133 Antigen
1
2015
19
0.030
 Why?
Cell Differentiation
2
2011
1993
0.030
 Why?
Cell Line, Transformed
1
1996
145
0.030
 Why?
Tissue Array Analysis
1
2015
56
0.030
 Why?
Hospital Charges
1
1996
44
0.030
 Why?
Hospitals, Teaching
1
2016
117
0.030
 Why?
Marriage
1
2017
121
0.030
 Why?
Caspase 3
1
2016
246
0.030
 Why?
Cystadenocarcinoma, Papillary
1
1995
5
0.030
 Why?
Carboplatin
1
1996
144
0.030
 Why?
RNA-Binding Proteins
1
2019
422
0.030
 Why?
Tumor Burden
1
2016
307
0.030
 Why?
Cell Cycle Proteins
1
2019
616
0.030
 Why?
Ataxia Telangiectasia Mutated Proteins
1
2015
66
0.030
 Why?
DNA Mismatch Repair
1
2015
49
0.030
 Why?
Ileus
1
2015
12
0.030
 Why?
Genes, p53
1
1995
72
0.030
 Why?
Disease Management
1
2019
629
0.030
 Why?
Urinary Retention
1
2015
21
0.030
 Why?
Income
1
2016
201
0.030
 Why?
Elective Surgical Procedures
1
2016
176
0.030
 Why?
Female Urogenital Diseases
1
2014
7
0.030
 Why?
Taxoids
1
2015
101
0.030
 Why?
RNA Interference
1
2016
469
0.030
 Why?
Antigens, Neoplasm
1
2017
318
0.030
 Why?
Morbidity
1
2015
324
0.030
 Why?
Receptors, Androgen
1
2015
150
0.030
 Why?
Multivariate Analysis
2
1996
1509
0.030
 Why?
Intraoperative Complications
1
2015
138
0.030
 Why?
Drug Administration Schedule
1
2016
786
0.030
 Why?
Blood Volume
1
2014
61
0.030
 Why?
Sensitivity and Specificity
1
2019
1941
0.030
 Why?
Reference Values
1
1996
815
0.030
 Why?
Bleomycin
1
1996
248
0.030
 Why?
Bevacizumab
1
2015
138
0.030
 Why?
Infusions, Parenteral
1
2014
40
0.030
 Why?
Point Mutation
1
1995
235
0.030
 Why?
Polyethyleneimine
1
2014
18
0.030
 Why?
Histones
1
2019
637
0.030
 Why?
Hemostatics
1
2014
51
0.030
 Why?
Pelvis
1
2015
106
0.030
 Why?
DNA, Viral
1
1996
362
0.030
 Why?
Insurance, Health
1
2016
283
0.030
 Why?
Deoxycytidine
1
2015
179
0.030
 Why?
Receptors, Progesterone
1
2015
350
0.030
 Why?
Tumor Suppressor Proteins
1
2016
327
0.030
 Why?
Drainage
1
2014
173
0.030
 Why?
Anemia
1
2015
170
0.030
 Why?
Preoperative Care
1
2015
361
0.030
 Why?
Urban Population
1
2016
479
0.030
 Why?
Thrombocytopenia
1
2015
200
0.020
 Why?
Gene Transfer Techniques
1
2014
171
0.020
 Why?
Polymorphism, Single-Stranded Conformational
3
1998
25
0.020
 Why?
Patient Readmission
1
2018
697
0.020
 Why?
Referral and Consultation
1
2018
782
0.020
 Why?
Membrane Proteins
1
2019
1164
0.020
 Why?
Ultrasonography
1
2016
761
0.020
 Why?
Biomarkers
1
2024
4155
0.020
 Why?
Linear Models
1
1994
849
0.020
 Why?
Cholesterol
1
2014
412
0.020
 Why?
Rural Population
1
2016
566
0.020
 Why?
Zinc Finger E-box-Binding Homeobox 1
1
2011
24
0.020
 Why?
Analysis of Variance
1
1994
1314
0.020
 Why?
Perioperative Period
1
2011
56
0.020
 Why?
Protein Kinase Inhibitors
1
2017
916
0.020
 Why?
Mutant Proteins
1
2011
103
0.020
 Why?
DNA Fragmentation
1
2011
41
0.020
 Why?
Comorbidity
1
2016
1619
0.020
 Why?
Risk Reduction Behavior
1
2013
220
0.020
 Why?
Fas Ligand Protein
1
2011
60
0.020
 Why?
Hyperplasia
1
2011
175
0.020
 Why?
Neovascularization, Pathologic
1
2012
300
0.020
 Why?
Neoplasm Transplantation
1
2011
253
0.020
 Why?
Tomography, X-Ray Computed
2
2014
2680
0.020
 Why?
Administration, Oral
1
2012
817
0.020
 Why?
Polymorphism, Single Nucleotide
1
2017
2189
0.020
 Why?
Epithelial-Mesenchymal Transition
1
2011
208
0.020
 Why?
Pregnancy Complications
1
2014
527
0.020
 Why?
Antibodies, Monoclonal, Humanized
1
2015
806
0.020
 Why?
Regression Analysis
1
2011
1024
0.020
 Why?
Anti-Bacterial Agents
2
2014
1809
0.020
 Why?
Polyethylene Glycols
1
2014
641
0.020
 Why?
Receptors, Urokinase Plasminogen Activator
1
2008
15
0.020
 Why?
Patient Discharge
1
2015
897
0.020
 Why?
Injections, Subcutaneous
1
2008
157
0.020
 Why?
Blotting, Western
1
2011
1228
0.020
 Why?
Placebos
1
2008
199
0.020
 Why?
Mice, Hairless
1
2008
60
0.020
 Why?
Enzyme Inhibitors
1
2011
840
0.020
 Why?
Sulfonamides
1
2011
513
0.020
 Why?
Quality Improvement
1
2015
1176
0.020
 Why?
Molecular Sequence Data
3
1996
2900
0.020
 Why?
Chromosome Mapping
2
1998
522
0.020
 Why?
Genetic Markers
2
1998
344
0.020
 Why?
Receptors, Cell Surface
1
2008
385
0.020
 Why?
Frameshift Mutation
2
1996
32
0.020
 Why?
Cross-Sectional Studies
1
2017
5474
0.010
 Why?
Gene Deletion
2
1998
391
0.010
 Why?
Carcinosarcoma
1
2005
21
0.010
 Why?
Cohort Studies
1
2015
5726
0.010
 Why?
DNA Mutational Analysis
2
1996
398
0.010
 Why?
Colorado
1
2014
4576
0.010
 Why?
Severity of Illness Index
1
2011
2841
0.010
 Why?
Obesity
1
2016
2994
0.010
 Why?
Base Sequence
2
1996
2181
0.010
 Why?
Electrophoresis, Gel, Pulsed-Field
1
2001
24
0.010
 Why?
Metronidazole
1
2001
20
0.010
 Why?
Genes, rRNA
1
2001
41
0.010
 Why?
Microbial Sensitivity Tests
1
2001
361
0.010
 Why?
DNA, Bacterial
1
2001
337
0.010
 Why?
RNA, Ribosomal, 16S
1
2001
549
0.010
 Why?
Loss of Heterozygosity
1
1998
51
0.010
 Why?
Microsatellite Repeats
1
1998
167
0.010
 Why?
Actuarial Analysis
1
1996
26
0.010
 Why?
Ecosystem
1
2001
596
0.010
 Why?
Genes, Neoplasm
1
1995
22
0.010
 Why?
BRCA1 Protein
1
1995
76
0.010
 Why?
Sequence Analysis, DNA
1
1998
811
0.010
 Why?
Age of Onset
1
1996
520
0.010
 Why?
Introns
1
1995
258
0.010
 Why?
Exons
1
1995
354
0.010
 Why?
Amino Acid Sequence
1
1995
2139
0.010
 Why?
Male
1
2017
67801
0.010
 Why?
Behbakht's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (455) concept(s)
_
Co-Authors Expand Description
See all (55) people
_
Similar People Expand Description
See all (60) people
_
Same Department Expand Description
Search Department
Physical Neighbors Expand Description
_

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)